Gamma Knife Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Description

The Gamma Knife Market has experienced significant growth, generating global revenue of approximately US$ 199 Million in 2024. The market is poised for continued expansion projected to reach an estimated valuation of around US$ 300 Million by the end of 2031. Several factors contribute to the growth of the Gamma Knife Market.

Gamma Knife for Non-Invasive Treatment

One of the main drivers of market expansion for the Gamma Knife is the worldwide increase in obesity cases. Doctors are recommending Gamma Knife procedures to obese patients due to its non-invasive nature. Non-invasive procedures hold more than 50% of the market share for aesthetic medicine, creating significant potential for Gamma Knife procedures.

Effective Stereotactic Radiosurgery

Stereotactic radiosurgery has become an alternative to conventional craniotomy procedures for treating cancer. The Gamma Knife method is widely used because it targets tumor cells without harming healthy cells, resulting in fewer adverse effects. It offers better visualization, remote accessibility, and team communication options.

Rising Prevalence of Neurological Disorders

A significant portion of the population, especially the elderly, is affected by various neurological disorders such as multiple sclerosis, Parkinson's disease, brain tumors, epilepsy, dementia, and stroke. Gamma Knife radiosurgery delivers targeted gamma radiation beams to the tumor site, making it suitable for treating complex neurological disorders. The quick recovery time and non-invasive nature of the procedure contribute to future market growth.

How Can the Global Market Grow?

"Rising Prevalence of Brain Tumors and Combination Treatment Therapies"

Brain tumors rank eighth in the list of most common cancers and third in cancer-related deaths among individuals aged 40 and older, according to the American Cancer Society. The increasing aging population is expected to drive demand for brain tumor treatment and rehabilitation, positively impacting market growth. Gamma Knife radiosurgery is a suitable treatment for numerous brain metastases, offering high integral dosage to the tumor with minimal impact on nearby healthy brain tissue. Combining biological and immunological agents with Gamma Knife radiosurgery further enhances treatment options.

Factors Affecting Market Growth:

"High Cost and Limited Awareness"

The high cost of Gamma Knife radiotherapy machines and associated investment and maintenance expenses may deter adoption in emerging economies, potentially affecting market growth. These machines are more expensive than other radiation equipment. Additionally, a dearth of skilled specialists who can operate Gamma Knife equipment may limit market expansion.

Why is the U.S. Market Booming?

The Gamma Knife procedure's less invasive nature compared to other treatments makes it the preferred choice in the United States. Rising disposable income also contributes to increased accessibility, fueling market growth.

Will Germany Be a Lucrative Market for Gamma Knife?

Major companies in the Gamma Knife industry are investing in research and development to modify existing models with the latest technologies, further stimulating market growth.

How is Japan Emerging as a Prominent Market?

Japan is expected to witness increased market share due to a rising incidence of vascular abnormalities, which result from lifestyle factors affecting many citizens.

Competitive Landscape:

Leading market players are strengthening their positions through mergers and acquisitions. Additionally, players are forming strategic alliances with competitors in other markets to drive growth.

Key Companies Profiled:

Elekta AB
Varian Medical Systems
Huiheng Medical, Inc.
MASEP Medical Science Technology Development (Shenzhen) Co., Ltd.
Akesis Inc.
Cyber Medical Corporation Limited.
Masep Infini Global, Inc.
Nordion, Inc.
Hokai
ET Medical Group
American Shared Hospital Services

Market Segmentation

Disease Indication:

Brain Metastasis
Cancer
Arteriovenous Malformation (AVM)
Trigeminal Neuralgia
Others

Organ Treated:

Head
Neck
Others

Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

1. Executive Summary

1.1. Global Gamma Knife Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Gamma Knife Market Outlook, 2018 - 2031

3.1. Global Gamma Knife Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Brain Metastasis
  - 3.1.1.2. Cancer
  - 3.1.1.3. Arteriovenous Malformation (AVM)
  - 3.1.1.4. Trigeminal Neuralgia
  - 3.1.1.5. Others
3.2. Global Gamma Knife Market Outlook, by Organ Treated, Value (US$ Bn), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Head
  - 3.2.1.2. Neck
  - 3.2.1.3. Others
3.3. Global Gamma Knife Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. North America
  - 3.3.1.2. Europe
  - 3.3.1.3. Asia Pacific
  - 3.3.1.4. Latin America
  - 3.3.1.5. Middle East & Africa

4. North America Gamma Knife Market Outlook, 2018 - 2031

4.1. North America Gamma Knife Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Brain Metastasis
  - 4.1.1.2. Cancer
  - 4.1.1.3. Arteriovenous Malformation (AVM)
  - 4.1.1.4. Trigeminal Neuralgia
  - 4.1.1.5. Others
4.2. North America Gamma Knife Market Outlook, by Organ Treated, Value (US$ Bn), 2018 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Head
  - 4.2.1.2. Neck
  - 4.2.1.3. Others
4.3. North America Gamma Knife Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. U.S. Gamma Knife Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 4.3.1.2. U.S. Gamma Knife Market by Organ Treated, Value (US$ Bn), 2018 - 2031
  - 4.3.1.3. Canada Gamma Knife Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 4.3.1.4. Canada Gamma Knife Market by Organ Treated, Value (US$ Bn), 2018 - 2031
- 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Gamma Knife Market Outlook, 2018 - 2031

5.1. Europe Gamma Knife Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Brain Metastasis
  - 5.1.1.2. Cancer
  - 5.1.1.3. Arteriovenous Malformation (AVM)
  - 5.1.1.4. Trigeminal Neuralgia
  - 5.1.1.5. Others
5.2. Europe Gamma Knife Market Outlook, by Organ Treated, Value (US$ Bn), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Head
  - 5.2.1.2. Neck
  - 5.2.1.3. Others
5.3. Europe Gamma Knife Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Germany Gamma Knife Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 5.3.1.2. Germany Gamma Knife Market by Organ Treated, Value (US$ Bn), 2018 - 2031
  - 5.3.1.3. U.K. Gamma Knife Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 5.3.1.4. U.K. Gamma Knife Market by Organ Treated, Value (US$ Bn), 2018 - 2031
  - 5.3.1.5. France Gamma Knife Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 5.3.1.6. France Gamma Knife Market by Organ Treated, Value (US$ Bn), 2018 - 2031
  - 5.3.1.7. Italy Gamma Knife Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 5.3.1.8. Italy Gamma Knife Market by Organ Treated, Value (US$ Bn), 2018 - 2031
  - 5.3.1.9. Turkey Gamma Knife Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 5.3.1.10. Turkey Gamma Knife Market by Organ Treated, Value (US$ Bn), 2018 - 2031
  - 5.3.1.11. Russia Gamma Knife Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 5.3.1.12. Russia Gamma Knife Market by Organ Treated, Value (US$ Bn), 2018 - 2031
  - 5.3.1.13. Rest of Europe Gamma Knife Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 5.3.1.14. Rest of Europe Gamma Knife Market by Organ Treated, Value (US$ Bn), 2018 - 2031
- 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Gamma Knife Market Outlook, 2018 - 2031

6.1. Asia Pacific Gamma Knife Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Brain Metastasis
  - 6.1.1.2. Cancer
  - 6.1.1.3. Arteriovenous Malformation (AVM)
  - 6.1.1.4. Trigeminal Neuralgia
  - 6.1.1.5. Others
6.2. Asia Pacific Gamma Knife Market Outlook, by Organ Treated, Value (US$ Bn), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Head
  - 6.2.1.2. Neck
  - 6.2.1.3. Others
- 6.2.2. BPS Analysis/Market Attractiveness Analysis
6.3. Asia Pacific Gamma Knife Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. China Gamma Knife Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 6.3.1.2. China Gamma Knife Market by Organ Treated, Value (US$ Bn), 2018 - 2031
  - 6.3.1.3. Japan Gamma Knife Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 6.3.1.4. Japan Gamma Knife Market by Organ Treated, Value (US$ Bn), 2018 - 2031
  - 6.3.1.5. South Korea Gamma Knife Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 6.3.1.6. South Korea Gamma Knife Market by Organ Treated, Value (US$ Bn), 2018 - 2031
  - 6.3.1.7. India Gamma Knife Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 6.3.1.8. India Gamma Knife Market by Organ Treated, Value (US$ Bn), 2018 - 2031
  - 6.3.1.9. Southeast Asia Gamma Knife Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 6.3.1.10. Southeast Asia Gamma Knife Market by Organ Treated, Value (US$ Bn), 2018 - 2031
  - 6.3.1.11. Rest of Asia Pacific Gamma Knife Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 6.3.1.12. Rest of Asia Pacific Gamma Knife Market by Organ Treated, Value (US$ Bn), 2018 - 2031
- 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Gamma Knife Market Outlook, 2018 - 2031

7.1. Latin America Gamma Knife Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Brain Metastasis
  - 7.1.1.2. Cancer
  - 7.1.1.3. Arteriovenous Malformation (AVM)
  - 7.1.1.4. Trigeminal Neuralgia
  - 7.1.1.5. Others
7.2. Latin America Gamma Knife Market Outlook, by Organ Treated, Value (US$ Bn), 2018 - 2031
- 7.2.2. BPS Analysis/Market Attractiveness Analysis
7.3. Latin America Gamma Knife Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Brazil Gamma Knife Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 7.3.1.2. Brazil Gamma Knife Market by Organ Treated, Value (US$ Bn), 2018 - 2031
  - 7.3.1.3. Mexico Gamma Knife Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 7.3.1.4. Mexico Gamma Knife Market by Organ Treated, Value (US$ Bn), 2018 - 2031
  - 7.3.1.5. Argentina Gamma Knife Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 7.3.1.6. Argentina Gamma Knife Market by Organ Treated, Value (US$ Bn), 2018 - 2031
  - 7.3.1.7. Rest of Latin America Gamma Knife Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 7.3.1.8. Rest of Latin America Gamma Knife Market by Organ Treated, Value (US$ Bn), 2018 - 2031
- 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Gamma Knife Market Outlook, 2018 - 2031

8.1. Middle East & Africa Gamma Knife Market Outlook, by Disease Indication, Value (US$ Bn), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Brain Metastasis
  - 8.1.1.2. Cancer
  - 8.1.1.3. Arteriovenous Malformation (AVM)
  - 8.1.1.4. Trigeminal Neuralgia
  - 8.1.1.5. Others
8.2. Middle East & Africa Gamma Knife Market Outlook, by Organ Treated, Value (US$ Bn), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Head
  - 8.2.1.2. Neck
  - 8.2.1.3. Others
- 8.2.2. BPS Analysis/Market Attractiveness Analysis
8.3. Middle East & Africa Gamma Knife Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. GCC Gamma Knife Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 8.3.1.2. GCC Gamma Knife Market by Organ Treated, Value (US$ Bn), 2018 - 2031
  - 8.3.1.3. South Africa Gamma Knife Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 8.3.1.4. South Africa Gamma Knife Market by Organ Treated, Value (US$ Bn), 2018 - 2031
  - 8.3.1.5. Egypt Gamma Knife Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 8.3.1.6. Egypt Gamma Knife Market by Organ Treated, Value (US$ Bn), 2018 - 2031
  - 8.3.1.7. Nigeria Gamma Knife Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 8.3.1.8. Nigeria Gamma Knife Market by Organ Treated, Value (US$ Bn), 2018 - 2031
  - 8.3.1.9. Rest of Middle East & Africa Gamma Knife Market by Disease Indication, Value (US$ Bn), 2018 - 2031
  - 8.3.1.10. Rest of Middle East & Africa Gamma Knife Market by Organ Treated, Value (US$ Bn), 2018 - 2031
- 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. By Disease Indication vs by Organ Treated Heatmap
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
- 9.4.1. Elekta AB
  - 9.4.1.1. Company Overview
  - 9.4.1.2. Therapy Portfolio
  - 9.4.1.3. Financial Overview
  - 9.4.1.4. Business Strategies and Development
- 9.4.2. Varian Medical Systems
  - 9.4.2.1. Company Overview
  - 9.4.2.2. Therapy Portfolio
  - 9.4.2.3. Financial Overview
  - 9.4.2.4. Business Strategies and Development
- 9.4.3. Huiheng Medical, Inc.
  - 9.4.3.1. Company Overview
  - 9.4.3.2. Therapy Portfolio
  - 9.4.3.3. Financial Overview
  - 9.4.3.4. Business Strategies and Development
- 9.4.4. MASEP Medical Science Technology Development (Shenzhen) Co., Ltd.
  - 9.4.4.1. Company Overview
  - 9.4.4.2. Therapy Portfolio
  - 9.4.4.3. Financial Overview
  - 9.4.4.4. Business Strategies and Development
- 9.4.5. Akesis Inc.
  - 9.4.5.1. Company Overview
  - 9.4.5.2. Therapy Portfolio
  - 9.4.5.3. Financial Overview
  - 9.4.5.4. Business Strategies and Development
- 9.4.6. Cyber Medical Corporation Limited.
  - 9.4.6.1. Company Overview
  - 9.4.6.2. Therapy Portfolio
  - 9.4.6.3. Financial Overview
  - 9.4.6.4. Business Strategies and Development
- 9.4.7. Masep Infini Global, Inc.
  - 9.4.7.1. Company Overview
  - 9.4.7.2. Therapy Portfolio
  - 9.4.7.3. Financial Overview
  - 9.4.7.4. Business Strategies and Development
- 9.4.8. Nordion, Inc.
  - 9.4.8.1. Company Overview
  - 9.4.8.2. Therapy Portfolio
  - 9.4.8.3. Financial Overview
  - 9.4.8.4. Business Strategies and Development
- 9.4.9. Hokai
  - 9.4.9.1. Company Overview
  - 9.4.9.2. Therapy Portfolio
  - 9.4.9.3. Financial Overview
  - 9.4.9.4. Business Strategies and Development
- 9.4.10. ET Medical Group
  - 9.4.10.1. Company Overview
  - 9.4.10.2. Therapy Portfolio
  - 9.4.10.3. Financial Overview
  - 9.4.10.4. Business Strategies and Development
- 9.4.11. American Shared Hospital Services
  - 9.4.11.1. Company Overview
  - 9.4.11.2. Therapy Portfolio
  - 9.4.11.3. Financial Overview
  - 9.4.11.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations